Related Experiment Video

Updated: Apr 5, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.9K

Current Phase II drugs under investigation for the treatment of limb ischemia

Stavros Spiliopoulos1, Panagiotis Kitrou1, Konstantinos Katsanos2

  • 1a 1 Patras University Hospital, Department of Interventional Radiology , Patras 26504, Greece +30 2613 603 219; stavspiliop@upatras.gr.

Expert Opinion on Investigational Drugs
|August 22, 2015
PubMed
Abstract

Insights

Peripheral arterial disease affects millions, with critical limb ischemia (CLI) leading to amputation. New endovascular treatments and therapeutic angiogenesis show promise for improving limb salvage and patient outcomes.

Area of Science:

  • Vascular Medicine
  • Interventional Cardiology
  • Regenerative Medicine

Background:

  • Peripheral arterial disease (PAD) affects over 20 million Europeans, with critical limb ischemia (CLI) posing significant risks.
  • CLI has a poor prognosis without treatment, often leading to limb loss and high mortality.
  • Current gold standard treatments involve risk factor modification and revascularization, with limited systemic pharmacological options.

Purpose of the Study:

  • To review current local and systemic pharmacological treatments for CLI.
  • To focus on Phase II clinical trials for novel CLI therapies.
  • To explore emerging strategies like therapeutic angiogenesis.

Main Methods:

  • Systematic review of literature on endovascular and pharmaco-biological therapies for CLI.
  • Analysis of Phase II clinical trial data for pharmacological agents.
  • Evaluation of gene and stem cell therapy concepts for therapeutic angiogenesis.

Main Results:

  • Novel endovascular technologies combining angioplasty with local drug delivery are advancing treatment standards.
  • New antithrombotic agents are expected to further enhance revascularization outcomes.
  • Therapeutic angiogenesis, via gene and stem cell therapy, shows potential for increasing ischemic tissue perfusion.

Conclusions:

  • Endovascular innovations and local drug delivery are becoming standard for limb ischemia management.
  • Antithrombotic agents and therapeutic angiogenesis offer promising avenues for improving limb salvage.
  • Combining revascularization with microcirculation enhancement through gene or stem cell therapy could significantly improve outcomes.
Keywords:
Phase II trialscritical limb ischemiadrug therapydrug-coated balloonsdrug-eluting stentsendovascualar treatmenttherapeutic angiogenesis

More Related Videos

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.9K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.4K

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
583
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
681
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
609
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
618